| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Insulin (basal ± rapid)[1] | Insulin therapy | Start NPH 0.1 U/kg/day at night ± rapid analogue 0.05 U/kg per meal; titrate by SMBG. Total dose typically increases 50% by third trimester | Not applicable — pregnancy use only | First-line pharmacotherapy in GDM; aspart, lispro, glargine, detemir all safe in pregnancy; teach self-administration and hypoglycaemia recognition |
| Metformin[1] | Biguanide | 500 mg PO BD, titrate to 1000 mg BD as tolerated | Not applicable — pregnancy use only | Acceptable alternative or adjunct to insulin (FOGSI 2023, NICE NG3); long-term safety good but crosses placenta — counsel on uncertainties; ~30–50% require insulin addition |
| Glyburide (alternative — not preferred)[1] | Sulfonylurea | 2.5–5 mg PO BD; max 20 mg/day | — | Less preferred than insulin or metformin due to neonatal hypoglycaemia and macrosomia signal; reserve for cases where insulin and metformin both unsuitable |
Screening, glycaemic targets, lifestyle and pharmacological therapy for hyperglycaemia first detected in pregnancy and postpartum follow-up.